Cogent Biosciences announced it will participate in the Jefferies Global Healthcare Conference on June 3, 2026, presenting its progress in developing precision therapies for genetically defined diseases. The company also granted inducement equity awards, including stock options and restricted stock units, to six new employees as part of its 2020 Inducement Plan. These moves highlight Cogent's ongoing efforts to advance its clinical programs, including bezuclastinib for Systemic Mastocytosis and Gastrointestinal Stromal Tumors, and to strengthen its team for future growth.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
